![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CX3CL1 |
Gene summary for CX3CL1 |
![]() |
Gene information | Species | Human | Gene symbol | CX3CL1 | Gene ID | 6376 |
Gene name | C-X3-C motif chemokine ligand 1 | |
Gene Alias | ABCD-3 | |
Cytomap | 16q21 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | A0N0N7 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6376 | CX3CL1 | LZE4T | Human | Esophagus | ESCC | 2.32e-10 | 1.04e-01 | 0.0811 |
6376 | CX3CL1 | LZE5T | Human | Esophagus | ESCC | 2.94e-03 | -2.92e-04 | 0.0514 |
6376 | CX3CL1 | LZE8T | Human | Esophagus | ESCC | 6.67e-08 | 2.02e-01 | 0.067 |
6376 | CX3CL1 | LZE21T | Human | Esophagus | ESCC | 1.83e-05 | 5.53e-01 | 0.0655 |
6376 | CX3CL1 | P1T-E | Human | Esophagus | ESCC | 9.34e-05 | 6.28e-01 | 0.0875 |
6376 | CX3CL1 | P2T-E | Human | Esophagus | ESCC | 4.34e-04 | 4.40e-01 | 0.1177 |
6376 | CX3CL1 | P4T-E | Human | Esophagus | ESCC | 1.33e-11 | -3.29e-02 | 0.1323 |
6376 | CX3CL1 | P5T-E | Human | Esophagus | ESCC | 3.37e-06 | 2.72e-01 | 0.1327 |
6376 | CX3CL1 | P8T-E | Human | Esophagus | ESCC | 1.20e-36 | 1.27e+00 | 0.0889 |
6376 | CX3CL1 | P10T-E | Human | Esophagus | ESCC | 3.73e-05 | -1.81e-01 | 0.116 |
6376 | CX3CL1 | P11T-E | Human | Esophagus | ESCC | 2.52e-07 | 7.25e-01 | 0.1426 |
6376 | CX3CL1 | P12T-E | Human | Esophagus | ESCC | 3.44e-04 | 1.46e-01 | 0.1122 |
6376 | CX3CL1 | P15T-E | Human | Esophagus | ESCC | 6.94e-14 | 5.78e-01 | 0.1149 |
6376 | CX3CL1 | P16T-E | Human | Esophagus | ESCC | 3.50e-03 | 2.44e-01 | 0.1153 |
6376 | CX3CL1 | P22T-E | Human | Esophagus | ESCC | 1.36e-16 | 4.19e-02 | 0.1236 |
6376 | CX3CL1 | P23T-E | Human | Esophagus | ESCC | 2.74e-03 | 6.08e-02 | 0.108 |
6376 | CX3CL1 | P26T-E | Human | Esophagus | ESCC | 1.01e-22 | 7.38e-01 | 0.1276 |
6376 | CX3CL1 | P27T-E | Human | Esophagus | ESCC | 1.87e-05 | 2.31e-01 | 0.1055 |
6376 | CX3CL1 | P30T-E | Human | Esophagus | ESCC | 3.09e-08 | 7.85e-01 | 0.137 |
6376 | CX3CL1 | P32T-E | Human | Esophagus | ESCC | 1.11e-08 | 1.12e-01 | 0.1666 |
Page: 1 2 3 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003223312 | Liver | HCC | positive regulation of actin filament bundle assembly | 38/7958 | 63/18723 | 3.27e-03 | 1.50e-02 | 38 |
GO:00507693 | Liver | HCC | positive regulation of neurogenesis | 116/7958 | 225/18723 | 3.67e-03 | 1.63e-02 | 116 |
GO:0031663 | Liver | HCC | lipopolysaccharide-mediated signaling pathway | 36/7958 | 60/18723 | 4.68e-03 | 2.01e-02 | 36 |
GO:00712196 | Liver | HCC | cellular response to molecule of bacterial origin | 113/7958 | 221/18723 | 5.73e-03 | 2.38e-02 | 113 |
GO:00510913 | Liver | HCC | positive regulation of DNA-binding transcription factor activity | 131/7958 | 260/18723 | 5.98e-03 | 2.45e-02 | 131 |
GO:01501461 | Liver | HCC | cell junction disassembly | 15/7958 | 21/18723 | 7.03e-03 | 2.80e-02 | 15 |
GO:00713471 | Liver | HCC | cellular response to interleukin-1 | 61/7958 | 113/18723 | 8.98e-03 | 3.46e-02 | 61 |
GO:003223122 | Liver | HCC | regulation of actin filament bundle assembly | 57/7958 | 105/18723 | 9.73e-03 | 3.66e-02 | 57 |
GO:007135611 | Liver | HCC | cellular response to tumor necrosis factor | 115/7958 | 229/18723 | 1.08e-02 | 3.99e-02 | 115 |
GO:00420631 | Liver | HCC | gliogenesis | 148/7958 | 301/18723 | 1.10e-02 | 4.07e-02 | 148 |
GO:200123320 | Oral cavity | OSCC | regulation of apoptotic signaling pathway | 242/7305 | 356/18723 | 6.66e-29 | 3.24e-26 | 242 |
GO:002241119 | Oral cavity | OSCC | cellular component disassembly | 283/7305 | 443/18723 | 9.57e-27 | 3.37e-24 | 283 |
GO:200123420 | Oral cavity | OSCC | negative regulation of apoptotic signaling pathway | 148/7305 | 224/18723 | 1.71e-16 | 1.36e-14 | 148 |
GO:009719120 | Oral cavity | OSCC | extrinsic apoptotic signaling pathway | 142/7305 | 219/18723 | 7.34e-15 | 4.55e-13 | 142 |
GO:004312218 | Oral cavity | OSCC | regulation of I-kappaB kinase/NF-kappaB signaling | 155/7305 | 249/18723 | 7.79e-14 | 4.14e-12 | 155 |
GO:004312310 | Oral cavity | OSCC | positive regulation of I-kappaB kinase/NF-kappaB signaling | 122/7305 | 186/18723 | 1.68e-13 | 8.52e-12 | 122 |
GO:004206020 | Oral cavity | OSCC | wound healing | 237/7305 | 422/18723 | 4.51e-13 | 2.18e-11 | 237 |
GO:000724910 | Oral cavity | OSCC | I-kappaB kinase/NF-kappaB signaling | 169/7305 | 281/18723 | 4.69e-13 | 2.25e-11 | 169 |
GO:190290520 | Oral cavity | OSCC | positive regulation of supramolecular fiber organization | 131/7305 | 209/18723 | 3.18e-12 | 1.27e-10 | 131 |
GO:000756818 | Oral cavity | OSCC | aging | 194/7305 | 339/18723 | 6.18e-12 | 2.33e-10 | 194 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0466810 | Esophagus | ESCC | TNF signaling pathway | 89/4205 | 114/8465 | 3.36e-10 | 4.01e-09 | 2.06e-09 | 89 |
hsa05163210 | Esophagus | ESCC | Human cytomegalovirus infection | 148/4205 | 225/8465 | 5.73e-07 | 4.00e-06 | 2.05e-06 | 148 |
hsa0466817 | Esophagus | ESCC | TNF signaling pathway | 89/4205 | 114/8465 | 3.36e-10 | 4.01e-09 | 2.06e-09 | 89 |
hsa0516338 | Esophagus | ESCC | Human cytomegalovirus infection | 148/4205 | 225/8465 | 5.73e-07 | 4.00e-06 | 2.05e-06 | 148 |
hsa0516312 | Liver | Cirrhotic | Human cytomegalovirus infection | 87/2530 | 225/8465 | 2.67e-03 | 1.10e-02 | 6.76e-03 | 87 |
hsa0516313 | Liver | Cirrhotic | Human cytomegalovirus infection | 87/2530 | 225/8465 | 2.67e-03 | 1.10e-02 | 6.76e-03 | 87 |
hsa046684 | Liver | HCC | TNF signaling pathway | 73/4020 | 114/8465 | 2.53e-04 | 1.19e-03 | 6.63e-04 | 73 |
hsa0516322 | Liver | HCC | Human cytomegalovirus infection | 131/4020 | 225/8465 | 6.86e-04 | 2.77e-03 | 1.54e-03 | 131 |
hsa0466811 | Liver | HCC | TNF signaling pathway | 73/4020 | 114/8465 | 2.53e-04 | 1.19e-03 | 6.63e-04 | 73 |
hsa0516332 | Liver | HCC | Human cytomegalovirus infection | 131/4020 | 225/8465 | 6.86e-04 | 2.77e-03 | 1.54e-03 | 131 |
hsa0516326 | Prostate | BPH | Human cytomegalovirus infection | 74/1718 | 225/8465 | 4.87e-06 | 3.92e-05 | 2.43e-05 | 74 |
hsa046688 | Prostate | BPH | TNF signaling pathway | 41/1718 | 114/8465 | 6.86e-05 | 4.35e-04 | 2.69e-04 | 41 |
hsa05163111 | Prostate | BPH | Human cytomegalovirus infection | 74/1718 | 225/8465 | 4.87e-06 | 3.92e-05 | 2.43e-05 | 74 |
hsa0466815 | Prostate | BPH | TNF signaling pathway | 41/1718 | 114/8465 | 6.86e-05 | 4.35e-04 | 2.69e-04 | 41 |
hsa0516327 | Prostate | Tumor | Human cytomegalovirus infection | 74/1791 | 225/8465 | 2.27e-05 | 1.79e-04 | 1.11e-04 | 74 |
hsa0466821 | Prostate | Tumor | TNF signaling pathway | 40/1791 | 114/8465 | 3.88e-04 | 2.07e-03 | 1.29e-03 | 40 |
hsa0516336 | Prostate | Tumor | Human cytomegalovirus infection | 74/1791 | 225/8465 | 2.27e-05 | 1.79e-04 | 1.11e-04 | 74 |
hsa0466831 | Prostate | Tumor | TNF signaling pathway | 40/1791 | 114/8465 | 3.88e-04 | 2.07e-03 | 1.29e-03 | 40 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
CX3CL1 | CX3CR1 | CX3CL1_CX3CR1 | CX3C | Breast | ADJ |
CX3CL1 | CX3CR1 | CX3CL1_CX3CR1 | CX3C | Breast | Healthy |
CX3CL1 | CX3CR1 | CX3CL1_CX3CR1 | CX3C | Lung | ADJ |
CX3CL1 | CX3CR1 | CX3CL1_CX3CR1 | CX3C | Lung | MIAC |
CX3CL1 | CX3CR1 | CX3CL1_CX3CR1 | CX3C | Prostate | ADJ |
CX3CL1 | CX3CR1 | CX3CL1_CX3CR1 | CX3C | Prostate | BPH |
CX3CL1 | CX3CR1 | CX3CL1_CX3CR1 | CX3C | THCA | ADJ |
CX3CL1 | CX3CR1 | CX3CL1_CX3CR1 | CX3C | THCA | Cancer |
CX3CL1 | CX3CR1 | CX3CL1_CX3CR1 | CX3C | THCA | PTC |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CX3CL1 | SNV | Missense_Mutation | rs760976659 | c.270N>A | p.Asp90Glu | p.D90E | P78423 | protein_coding | tolerated(0.06) | benign(0.065) | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CX3CL1 | SNV | Missense_Mutation | c.575N>G | p.Ser192Cys | p.S192C | P78423 | protein_coding | deleterious(0) | possibly_damaging(0.707) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
CX3CL1 | SNV | Missense_Mutation | c.184G>A | p.Ala62Thr | p.A62T | P78423 | protein_coding | deleterious(0.05) | probably_damaging(0.968) | TCGA-AR-A252-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
CX3CL1 | SNV | Missense_Mutation | novel | c.875N>G | p.Ser292Cys | p.S292C | P78423 | protein_coding | deleterious(0.01) | probably_damaging(0.936) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD |
CX3CL1 | SNV | Missense_Mutation | c.649N>A | p.Glu217Lys | p.E217K | P78423 | protein_coding | tolerated(0.13) | benign(0.147) | TCGA-C5-A1MJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
CX3CL1 | SNV | Missense_Mutation | c.761N>T | p.Pro254Leu | p.P254L | P78423 | protein_coding | tolerated(0.13) | benign(0.001) | TCGA-IR-A3LI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
CX3CL1 | SNV | Missense_Mutation | novel | c.293N>A | p.Arg98Gln | p.R98Q | P78423 | protein_coding | tolerated(1) | benign(0) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
CX3CL1 | SNV | Missense_Mutation | novel | c.528N>T | p.Gln176His | p.Q176H | P78423 | protein_coding | tolerated(0.14) | benign(0.215) | TCGA-ZJ-AAXF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
CX3CL1 | SNV | Missense_Mutation | c.824T>A | p.Phe275Tyr | p.F275Y | P78423 | protein_coding | deleterious(0) | possibly_damaging(0.693) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
CX3CL1 | SNV | Missense_Mutation | c.362N>C | p.Met121Thr | p.M121T | P78423 | protein_coding | tolerated(0.51) | benign(0) | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6376 | CX3CL1 | CELL SURFACE, DRUGGABLE GENOME | COMPLETE FREUND&APOS;S ADJUVANT | 15993821 | ||
6376 | CX3CL1 | CELL SURFACE, DRUGGABLE GENOME | ATEZOLIZUMAB | ATEZOLIZUMAB | 25428504 |
Page: 1 |